403 results about "Imaging agent" patented technology

In accordance with at least one aspect of this disclosure, there is provided an imaging agent, a including dye compound conjugated to an antigen specific targeting vector which can be particularly advantageous because their behavior in vivo can contribute to superior optical imaging properties, for example, by significantly increasing the target-to-background ratio of imaged tissues, leading to higher resolution imaging, and ultimately providing for better recognition of malignant tissue for resection and margin assessment and improved visualization during minimal invasive laparoscopic surgery, for example. A method of imaging tumor cells in a subject, can include, administering an imaging effective amount of an imaging agent according at least one embodiment of the invention; 2-4 hours after administration of the imaging agent, irradiating a region in the subject in which tumor cells are expected to be found with at a wavelength absorbed by the imaging agent; and detecting a signal from the imaging agent, thereby imaging the tumor cells, wherein the target-to-background ratio 2-4 hours after administration is from about 2.75 to about 15.

The invention is based, at least in part, on the discovery that replacement of a key bond in the near-infrared fluorophore with a carbon-carbon bond conjugation to a targeting ligand results in vastly increased stability as compared to NIR fluorophores without such a bond, while preserving ligand and zwitterionic properties. In at least one aspect, the invention provides an imaging agent dye comprising a charge-balanced imaging agent conjugated to a targeting vector, wherein the targeting vector is a PSMA binding vector, such as dPSMA-617 or KUE, a FAP binding vector, a bombesin receptor binding vector, or a somatostatin receptor binding vector, and the charge-balanced imaging agent is ZW-800-1, ZW-830-1, or ZW-700-1-Forte.

The invention provides a composition containing folic acid compounds and a near-infrared fluorescence capture system. The near-infrared fluorescence capture system comprises an imaging module, and the imaging module comprises a compound shown in the formula I or pharmaceutically acceptable salt of the compound. The compound shown in the formula I or the pharmaceutically acceptable salt of the compound can be used as a near-infrared fluorescence imaging agent, and is good in targeting property and clinical application prospect. # imgabs0 #

Disclosed are systems and methods for continuously detecting, and optionally classifying, abnormal perfusion patterns in tissue by means of fluorescence imaging. A computer implemented method for detecting (and / or identifying) one or more areas having an abnormal perfusion pattern in tissue of a subject, for example during a medical procedure, includes: continuously acquiring fluorescence images of the tissue, wherein the fluorescence images are associated with a fluorescent output signal correlated with an input signal defined by a series of boluses of at least one fluorescent imaging agent, and wherein the series of boluses is administered with a predefined and / or controlled duration between subsequent boluses, analyzing the fluorescence images, identifying at least one tissue area with normal perfusion, defining a normal perfusion pattern (in an intensity domain and) in a time domain, and detecting, in the fluorescence images, possible tissue areas with abnormal (non-normal) perfusion pattern.

The invention provides a target Her2 nuclide probe as well as a preparation method and application thereof, and relates to the technical field of nuclide probes. The target Her2 nuclide probe comprises a compound which is labeled by radionuclide and is shown in a formula I. The target Her2 nuclide probe can be used as a diagnosis and treatment reagent in human or animal Her2 protein high expression lesions, and is especially used as a tumor imaging agent and a radionuclide treatment drug. In animal experiments, the tumor / muscle ratio of the radioactive complex is high, and the radioactive complex has a good application prospect. And the formula I of the # imgabs0 # is shown in the specification.

The present invention relates to the nanoparticles (NP) of the invention, compositions thereof and their use as therapeutic agents, in particular in the field of oncology and / or as imaging agents. The NPs consist of first nanoparticles of at least one high-Z metal oxide material, to which smaller second nanoparticles are covalently bonded at the surface of the first nanoparticles. The second nanoparticles consist of a) at least one noble metal or at least one metal oxide, metal sulfide, metal selenide or metal sulfide / selenide as a Fenton or Fenton-like reaction catalyst. The NPs of the invention produce a surprising therapeutic effect when exposed to ionizing radiation such as X-rays, gamma-rays, protons, neutrons, radioisotopes and / or electron beams. Therefore, these NPs can be used as radiosensitizers in the field of oncology. These nanoparticles can also be used as contrast agents.

The invention discloses an auxiliary diagnosis and treatment system based on a large-scale language model, and belongs to the technical field of medical image analysis, and the auxiliary diagnosis and treatment system comprises a medical image agent based on a large-scale pre-training language model, a tool assembly and a storage pool module, the tool assembly comprises a report generation module, an image segmentation module, a focus detection module, a report evaluation module, a diagnosis and treatment assistant module and a storage pool module. According to the auxiliary diagnosis and treatment system based on the large-scale language model, natural languages input by a user are analyzed and converted into specific task prompts through the medical image intelligent body, complex medical image problems are automatically decomposed, tool assemblies are matched and called, detailed step-by-step solutions are generated, and compared with an existing device, the auxiliary diagnosis and treatment system based on the large-scale language model has the advantages that the efficiency is high; the problem that the operation is complex and not visual enough is avoided, the operation is simplified, and the use threshold is lowered.

Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described.

The present invention relates to MOFs for use in imaging and as radiolabeled tracers. More specifically, the present invention provides particles comprising MOFs, optionally at least one targeting moiety, and at least one short-lived radionuclide; compositions comprising the particles; the particles or compositions for use as imaging agents; the particles or compositions for use in methods for diagnosing proliferative diseases; the particles or compositions for use in methods for diagnosing chronic inflammatory diseases; and kits comprising particles comprising MOFs, optionally a targeting moiety, and a short-lived radionuclide cation.

The tumor stroma, which accounts for a large portion of the tumor mass, is an attractive target for the delivery of diagnostic and therapeutic compounds. Here, we focus specifically on a subpopulation of stromal cells known as cancer-associated fibroblasts, which are present in over 90% of epithelial cancers, including pancreatic, colon, and breast cancers. Cancer-associated fibroblasts are characterized by high expression of FAPs, which are undetectable in adult normal tissues but are associated with poor prognosis in cancer patients. The present invention provides small molecule radiopharmaceuticals and imaging agents based on FAP-specific inhibitors.

The invention relates to the technical field of pharmaceutical preparations, in particular to ultrasonic developing composite gel as well as a preparation method and application thereof. The invention provides ultrasonic developing composite gel, which is prepared from the following components in parts by mass: a gel matrix, an ultrasonic developing material and a pharmaceutically acceptable solvent, the concentration of the gel matrix in the ultrasonic developing composite gel is 1 to 500 mg / mL; the concentration of the ultrasonic developing material in the ultrasonic developing composite gel is 1-500 mg / mL; the gel matrix comprises one or more of a temperature sensitive type gel matrix, an injectable type gel matrix and an ion response type gel matrix; the ultrasonic developing material comprises an ultrasonic phase change developer and a high polymer material wrapping the ultrasonic phase change developer, and the ultrasonic developing material is of an ultrasonic developing microbubble structure. The ultrasonic development composite gel can enhance ultrasonic development in the embryo transplantation process and promote adhesion and implantation of an embryo and an endometrium.

Provided herein are lipid nanoparticle complex with nanoparticles cloaked in monocyte plasma membrane. The nanoparticles of the lipid nanoparticle complex can be loaded with imaging agents. Also provided are methods of using the lipid nanoparticle complex for targeting and imaging of atherosclerosis in a subject in need thereof.

Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.

There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2 Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.

The present invention is directed to compounds (macrocyclic compounds) and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjugates thereof, and the use of said compounds and immunoconjugates, radioimmunoconjugates thereof, in nuclear medicine as tracers and imaging agents.

The present disclosure regards PSMA targeting urea-based ligands comprising a PSMA targeting moiety, a linker, and a pyridazine moiety. The PSMA targeting urea-based ligands disclosed are suitable for use as radiopharmaceuticals, either as imaging agents, such as diagnostic agents, or for the treatment of prostate cancer or as theranostic agents.

Disclosed are methods for imaging inflammation associated with inflammatory bowel disease (IBD), including administering to a subject a prostate-specific membrane antigen (PSMA)-targeted imaging agent and taking an image.

There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.

A method for preparing an 18F-labeled imaging agent comprising a conjugate of a peptide having a binding specificity for programmed death ligand 1 (PD-L1) and a chelating moiety, and optionally a linker. In representative aspects, the 18F-labeled imaging agent is [18F]-DK222.

A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula (I) or of a salt or a solvate thereof. R1 is —R1aR1b— wherein R1a is absent, —CH2—, —O—, or —S—, and R1b is —CH2— or —CHF—. R2 is —(CH2)3—O—, —(CH2)3—, —(CH2)4—, —CH2—O—(CH2)2—, or —CH2—S—(CH2)2. R3 is ethylene fused to a tricyclic fused ring. L1, L2, L3, L4, L5b L5c, L6 and L7 are linkages (e.g. peptide bonds). Xbr is a branching atom. Rrad is a radiometal chelator. Ralb is an albumin binder. n1, n2, n3, n4, and n5 are integers. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases / conditions.

Provided herein are imaging agent-loaded cryopreserved platelets and platelet derivatives, such as MRI agent-loaded platelets and platelet derivatives, and methods of preparing and using the same. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent and a cell penetrating peptide. In some embodiments, methods of preparing MRI agent-loaded cryopreserved platelets or platelet derivatives in a dried powder, wherein the MRI agent-loaded cryopreserved platelets or the MRI agent-loaded platelet derivatives comprise an MRI agent complex covalently bonded to the surface of the cryopreserved platelets or the platelet derivatives.

The present disclosure relates to systems and methods for continuously detecting, and optionally classifying, abnormal perfusion patterns in tissue by means of fluorescence imaging. One embodiment relates to a computer implemented method for detecting (and / or identifying) one or more areas having an abnormal perfusion pattern in tissue of a subject, for example during a medical procedure, the method comprising the steps of: continuously acquiring fluorescence images of the tissue, wherein the fluorescence images are associated with a fluorescent output signal correlated with an input signal defined by a series of boluses of at least one fluorescent imaging agent, and wherein the series of boluses is administered with a predefined and / or controlled duration between subsequent boluses, analysing the fluorescence images, identifying at least one tissue area with normal perfusion, defining a normal perfusion pattern (in an intensity domain and) in a time domain, and detecting, in the fluorescence images, possible tissue areas with abnormal (non-normal) perfusion pattern.

The present invention discloses a bionic lumbar spine bone with X-ray imaging and its preparation method, which relates to the field of bionic technology of medical polymer materials. The technical solution is to stir and mix the raw materials of rigid polyurethane foam and then pour them into a lumbar spine bone mold for foaming to prepare the cancellous bone material of the bionic lumbar spine bone; use the blend modification of styrene-acrylic emulsion and SAN emulsion to prepare the material for bionic cortical bone; and then use the spraying or dipping process to attach the prepared cortical bone to the outer surface of the cancellous bone to form a bionic lumbar spine bone with X-ray imaging. By adding a water-soluble imaging agent in the emulsion synthesis, the present invention realizes the fine distribution of the imaging agent, significantly improves the contrast and clarity of X-ray imaging. Compared with the traditional materials relying on high-concentration inorganic imaging agents, the water-soluble imaging agent not only improves the biocompatibility and environmental protection, but also strengthens the hardness and wear resistance of the material through SAN resin, is applicable to diversified medical and industrial applications, and shows broad market potential.

The present invention relates to anti-CD 103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases. Also disclosed is an imaging agent comprising the anti-CD 103 antibody and a detectable label, wherein the antibody either does not block CD 103 binding to E-cadherin or at least partially blocks CD 103 binding to E-cadherin. The methods of treatment involve administering the anti CD 103 antibody which may be optionally coupled to a cytotoxic agent. Diseases to be treated include e.g. Hairy Cell leukemia, HCLv, intestinal and extraintestinal lymphomas, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Sezary Syndrome (SS), Alzheimer's disease, Parkinson's disease or multiple sclerosis.

The invention relates to a radionuclide labeled trimer probe 68Ga-TRAP-(FAPI) 3 targeting FAP and a preparation method thereof, Trap is used as a trivalent chelating platform, and three FAPI targeting units are covalently connected by clicking a chemical linking arm to form a trimer structure; the invention further relates to application of the 68Ga-TRAP-(FAPI) 3 probe in preparation of imaging agents or therapeutic drugs for diagnosing FAP positive diseases, experiments prove that the trimer probe is good in affinity and high in stability, and in cell experiments and animal experiments, the uptake rate of FAP positive cells is kept at a high level within 240 minutes; preclinical and preliminary clinical applications show that the tumor detection rate of the < 68 > Ga-TRAP-FAPI 3 in various cancer models is superior to that of < 18 > F-FDG, and compared with < 68 > Ga-FAPI-04, the < 68 > Ga-TRAP-FAPI 3 is clearer to display focuses (particularly tiny metastases), higher in uptake intensity and particularly outstanding in delayed imaging, and the < 68 > Ga-TRAP-FAPI 3 can be used for preparing a medicine for treating cancer. And a novel drug candidate with better performance is provided for precise diagnosis and staging of tumors and subsequent radionuclide targeted therapy.

The invention discloses a medical double-core-layer pressure-resistant sensing balloon and a preparation method thereof.The medical double-core-layer pressure-resistant sensing balloon comprises a balloon body connected with a catheter, the balloon body is of a double-core-layer shell layer structure, and a core layer comprises a developing and pressure sensing double-core structure; a developing agent is loaded in the inner core layer balloon, the position of the balloon is effectively displayed, it can be guaranteed that the core layer is not affected after the outer layer is damaged, the inner layer and the other core layer balloon can synchronously conduct pressure sensing, and the shell layer is a compression layer with toughness and bursting pressure and can be coated with a medicine coating. According to the medical double-core-layer high-pressure-resistant balloon provided by the invention, through the design of the internal double core layers, accurate control of pressure is effectively realized, and the problem that a developing agent leaks out of the brain after the outer layer of the balloon is broken in a trigeminal nerve minimally invasive puncture balloon compression operation is prevented; and by controlling the surface roughness of the outer layer, medicine coating can be carried out, so that vagus nerve reflex is prevented, and the problem of high risks of sudden blood pressure rise and sudden heartbeat arrest caused by compression in the operation process is solved.

Antibodies and antigen binding fragments thereof that specifically recognize and bind an epitope of elastin that is exposed and accessible in degraded elastic fiber are described. The antibodies and / or antigen binding fragments can be operably linked to a secondary component, including biologically active agents such as therapeutics and / or imaging agents. Optionally, the antibodies and / or antigen binding fragments thereof can be attached to a surface of a carrier, such as a particle, for specific binding and delivery of the carried agents to degraded elastic fiber.

The invention provides an FAPI trimer compound, a preparation method of the FAPI trimer compound, a PET developer based on the FAPI trimer compound and a preparation method of the developer. Amphipathic polyethylene glycol chains and trimeric structures in molecules of the FAPI trimer compound can improve in-vivo dynamic characteristics of the compound, and the in-vivo dynamic characteristics of the compound can be improved. The residence time in the tumor is prolonged; the PET imaging agent based on the FAPI trimer compound can improve the uptake and imaging effects of the PET imaging agent in tumors, and has good application prospects in PET imaging, preparation of drugs for diagnosing FAP-q expressed tumors and drugs for marking therapeutic nuclide (177Lu or 90Y) to treat the FAP-q expressed tumors in the future.